Catalyst Health Ventures

Catalyst Health Ventures is a Boston-based venture capital firm founded in 2008, specializing in early-stage investments within the healthcare and life sciences sectors. The firm focuses on technology solutions that address significant global clinical needs, particularly in oncology, cardiovascular disease, obesity, and women’s health. Catalyst Health Ventures employs a hands-on approach, collaborating closely with management teams and partners to foster the growth of innovative companies. Their investment strategy emphasizes pioneering technological solutions that aim to reduce treatment costs and enhance patient outcomes. By targeting areas such as therapeutic medical devices, diagnostics, digital health, and drug delivery, the firm seeks to minimize risks associated with scientific uncertainty while maximizing the potential of emerging ventures.

46 past transactions

Avive Solutions

Series A in 2022
Avive Solutions develops a next-generation Automated External Defibrillator (AED) and software solutions. Avive's AED enables anyone to positively impact the outcome of a Sudden Cardiac Arrest (SCA) rescue by building a more robust solution that addresses the problem of SCA in its entirety. The AED will remove barriers to respond to a SCA scenario. It is easy to purchase, easy to access in an emergency, easy to keep maintained, and most importantly easy to use effectively when it matters most. Avive Solutions is headquartered in Brisbane, California.

Epitel

Series A in 2022
Epitel is a digital health company developing a wearable, wireless EEG monitoring platform to provide accessible, affordable, and reliable for seizure detection.

PanTher Therapeutics

Series A in 2021
PanTher Therapeutics is on a mission to revolutionize cancer care with a proprietary treatment platform designed to enhance therapeutic response with minimal side effects. PanTher’s highly adaptable platform empowers oncologists to treat patients with life-threatening cancer by unlocking a drug’s full potential through direct, sustained treatment at the tumor site. This distinctive targeting capability uniquely positions PanTher to take on the deadliest and most difficult to treat cancers with a lead investigational candidate in pancreatic cancer.

Instylla

Series B in 2020
Instylla is a medical equipment supplier that provides liquid embolics of the next generation for interventional radiology. It is a Bedford, Massachusetts-based company. independently held firm with the major objective of developing next-generation liquid embolics for the radiology department. with early medical applications in peripheral hemostasis and interventional oncology. The EmbraceTM Hydrogel Embolic System, the company's initial product, and persistent embolization in these clinical situations.

Conformal Medical

Private Equity Round in 2020
Conformal Medical is an early stage medical device company developing devices to prevent stroke in patients with non-valvular atrial fibrillation. The company's proprietary technology will help left atrial appendage closure to meet its true potential. It was founded in 2016 and is headquartered in Nashua, New Hampshire.

AtaCor Medical

Series B in 2020
AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.

Aria CV

Series B in 2020
Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart.

Conformal Medical

Series B in 2018
Conformal Medical is an early stage medical device company developing devices to prevent stroke in patients with non-valvular atrial fibrillation. The company's proprietary technology will help left atrial appendage closure to meet its true potential. It was founded in 2016 and is headquartered in Nashua, New Hampshire.

Lantos Technologies

Venture Round in 2018
Lantos Technologies is the only FDA-cleared 3D ear scanning system that enables custom, in-ear products with superior comfort, sound quality, and performance. Our technology enables the efficient and effective delivery of customized hearing aids and other hearing-related products.

Saphena Medical

Series C in 2017
Saphena Medical is a medical device company that specializes in cardiovascular space. It offers Venapax, an all-in-one system that provides dissection and simultaneous branch ligation. It delivers a minimal-touch experience with a focus on specimen quality.

Cruzar Medsystems

Series B in 2017
Cruzar Medsystems Inc. operates in the healthcare industry manufacturing medical device designed to access peripheral vasculature. The company was incorporated in 2013 and is based in Braintree, Massachusetts.

Sera Prognostics

Series C in 2017
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.

nVision Medical

Series B in 2016
NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California. nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation. Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.

SpaceOAR

Series E in 2016
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Maxwell Health

Series C in 2016
Maxwell Health simplifies benefits and HR for small-to-mid-sized employers. The platform includes a marketplace that makes buying benefits intuitive for employees, tools that streamline HR processes including benefits administration and payroll, and a mobile app that makes using benefits easy. Their purpose is to help American families achieve health and financial well-being by modernizing how employees experience insurance, financial, and wellness benefits. The platform is provided by benefits advisors as well as insurance and retirement companies that license their technology. It was founded in 2012 and is headquartered in Boston, Massachusetts.

Aria CV

Series A in 2015
Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart.

Saphena Medical

Series B in 2015
Saphena Medical is a medical device company that specializes in cardiovascular space. It offers Venapax, an all-in-one system that provides dissection and simultaneous branch ligation. It delivers a minimal-touch experience with a focus on specimen quality.

Sera Prognostics

Series B in 2015
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.

Maxwell Health

Series B in 2014
Maxwell Health simplifies benefits and HR for small-to-mid-sized employers. The platform includes a marketplace that makes buying benefits intuitive for employees, tools that streamline HR processes including benefits administration and payroll, and a mobile app that makes using benefits easy. Their purpose is to help American families achieve health and financial well-being by modernizing how employees experience insurance, financial, and wellness benefits. The platform is provided by benefits advisors as well as insurance and retirement companies that license their technology. It was founded in 2012 and is headquartered in Boston, Massachusetts.

SevenOaks BioSystems

Series A in 2014
SevenOaks Biosystems, LLC focuses on developing autologous tissue generation equipment.

Sera Prognostics

Series B in 2014
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.

SpaceOAR

Series D in 2014
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Maxwell Health

Series A in 2013
Maxwell Health simplifies benefits and HR for small-to-mid-sized employers. The platform includes a marketplace that makes buying benefits intuitive for employees, tools that streamline HR processes including benefits administration and payroll, and a mobile app that makes using benefits easy. Their purpose is to help American families achieve health and financial well-being by modernizing how employees experience insurance, financial, and wellness benefits. The platform is provided by benefits advisors as well as insurance and retirement companies that license their technology. It was founded in 2012 and is headquartered in Boston, Massachusetts.

Cruzar Medsystems

Series A in 2013
Cruzar Medsystems Inc. operates in the healthcare industry manufacturing medical device designed to access peripheral vasculature. The company was incorporated in 2013 and is based in Braintree, Massachusetts.

nVision Medical

Series A in 2013
NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California. nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation. Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.

BIOCIUS Life Sciences

Venture Round in 2012
BIOCIUS Life Sciences, Inc. engages in the drug discovery research. The company was incorporated in 2009 and is based in Woburn, Massachusetts. BIOCIUS Life Sciences, Inc. operates as a subsidiary of BioTrove, Inc.

nVision Medical

Seed Round in 2011
NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California. nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation. Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.

Sera Prognostics

Series A in 2011
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.

Lantos Technologies

Venture Round in 2011
Lantos Technologies is the only FDA-cleared 3D ear scanning system that enables custom, in-ear products with superior comfort, sound quality, and performance. Our technology enables the efficient and effective delivery of customized hearing aids and other hearing-related products.

Allegro Diagnostics

Series A in 2011
Allegro Diagnostics was founded in 2006 by Jerome Brody, M.D., and Avrum Spira, M.D., MSc, faculty at the Boston University School of Medicine and thought leaders in the field of pulmonology. The company is currently headquartered in Maynard, Massachusetts.

Sera Prognostics

Series A in 2011
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.

SpaceOAR

Debt Financing in 2011
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Sera Prognostics

Seed Round in 2010
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.

Lantos Technologies

Venture Round in 2010
Lantos Technologies is the only FDA-cleared 3D ear scanning system that enables custom, in-ear products with superior comfort, sound quality, and performance. Our technology enables the efficient and effective delivery of customized hearing aids and other hearing-related products.

Vortex Medical

Series B in 2010
Vortex Medical is a medical device company focused on the design, development and commercialization.

SpaceOAR

Series B in 2009
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Vortex Medical

Series A in 2008
Vortex Medical is a medical device company focused on the design, development and commercialization.

BioTrove

Venture Round in 2006
BioTrove, Inc. provides micro and nano-scale technology platforms for life science and drug discovery research applications. The company offers OpenArray, a technology platform for relative gene expression analysis that advances genomic research in various life science fields, including agriculture, disease research, and public health; RapidFire, a technology platform that enables the screening of intractable drug targets via mass spectrometry based assay development; and RapidFire mass spectrometry hardware system, a native detection technology for drug screening and in vitro ADME applications.

BioTrove

Series B in 2005
BioTrove, Inc. provides micro and nano-scale technology platforms for life science and drug discovery research applications. The company offers OpenArray, a technology platform for relative gene expression analysis that advances genomic research in various life science fields, including agriculture, disease research, and public health; RapidFire, a technology platform that enables the screening of intractable drug targets via mass spectrometry based assay development; and RapidFire mass spectrometry hardware system, a native detection technology for drug screening and in vitro ADME applications.

Hansen Medical

Venture Round in 2005
Hansen Medical was born from the vision of creating a new generation of advanced medical robotics. The Sensei Robotic Catheter System is their first product.

GI Dynamics

Series B in 2004
GI Dynamics, Inc., a medical device company, develops therapies for the treatment of type 2 diabetes and related metabolic diseases in the United States. Its products also include EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. The company was founded in 2003 and is based in Lexington, Massachusetts.

BioTrove

Series B in 2004
BioTrove, Inc. provides micro and nano-scale technology platforms for life science and drug discovery research applications. The company offers OpenArray, a technology platform for relative gene expression analysis that advances genomic research in various life science fields, including agriculture, disease research, and public health; RapidFire, a technology platform that enables the screening of intractable drug targets via mass spectrometry based assay development; and RapidFire mass spectrometry hardware system, a native detection technology for drug screening and in vitro ADME applications.

BioTrove

Private Equity Round in 2002
BioTrove, Inc. provides micro and nano-scale technology platforms for life science and drug discovery research applications. The company offers OpenArray, a technology platform for relative gene expression analysis that advances genomic research in various life science fields, including agriculture, disease research, and public health; RapidFire, a technology platform that enables the screening of intractable drug targets via mass spectrometry based assay development; and RapidFire mass spectrometry hardware system, a native detection technology for drug screening and in vitro ADME applications.

Novazyme Pharmaceuticals

Series B in 2001
Novazyme Pharmaceuticals is a biotech startup that conducts research on a new experimental treatment for Pompe disease.

Novazyme Pharmaceuticals

Series A in 2000
Novazyme Pharmaceuticals is a biotech startup that conducts research on a new experimental treatment for Pompe disease.

EndoVia Medical

Series C in 2000
EndoVia Medical is a developer of physician-guided robotic systems for minimally invasive surgery. It develops the Laprotek system, a robotic instrument system for minimally invasive surgeries including general surgery, urology, gynecology, and bariatric surgery, and the ViaCath system, a user interface, and instrument control platform, that allows the surgeon to manipulate catheter instruments deep inside the patient.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.